Teon Therapeutics Announces First Patient Treated in Phase 1/2 Clinical Trial of TT-816, a Novel Oral Immune Checkpoint Inhibitor, in Patients with Advanced Solid Tumors

SAN FRANCISCO–(BUSINESS WIRE)–Teon Therapeutics (Teon), a clinical-stage biopharmaceutical company targeting metabolic signaling pathways and pioneering the development of G-Protein Coupled Receptor (GPCR) immuno-oncology therapies in difficult-to-treat cancers, today announced that…

Drug Enforcement Administration (DEA) Controlled Substances Module and Handbook 2022: Guide to Manufacturing, Storing, Securing, Shipping, Distributing, Importing, Exporting and Disposal – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Controlled Substances Module and Handbook” directory has been added to ResearchAndMarkets.com’s offering. You need easy-to-understand text that clarifies what each regulation under the Controlled Substances Act requires. The…